Blue Lake, CyanVac Report Positive Phase 2a Data for Intranasal COVID-19 Vaccine Candidate

Source :: Entertainment Close-up. December 11, 2024
Publication Year :: 2024
Abstract: Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, [...]

Subjects :: Biological products industry -- Product development
Vaccination -- Research
Clinical trials -- Research
Vaccines -- Product development -- Complications and side effects -- Research
Arts and entertainment industries

Tools